The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.
Lexeo’s IPO Raises $100M for Gene Therapies That Treat the Heart, Protect the Brain
